What is the recommended treatment for oral herpes (herpes simplex virus type 1)?

Treatment of Oral Herpes (HSV-1)

For first-episode oral herpes, treat with oral acyclovir 400 mg three times daily for 7-10 days, or valacyclovir 1 g twice daily for 7-10 days. 1

Clinical Approach by Presentation

First Clinical Episode (Primary Infection)

The most recent guideline evidence supports systemic antiviral therapy for primary oral HSV-1 infection, including severe presentations like gingivostomatitis or pharyngitis 1.

Recommended regimens:

• Acyclovir 400 mg orally 3 times daily for 7-10 days (may use higher dose of 400 mg 5 times daily for severe oral infection)
• Valacyclovir 1 g orally twice daily for 7-10 days
• Famciclovir 250 mg orally 3 times daily for 7-10 days

Treatment should be extended if healing is incomplete after 10 days 1. The higher acyclovir dosing (400 mg five times daily) was specifically studied for first-episode oral infections including stomatitis and pharyngitis, though it remains unclear whether these mucosal infections truly require higher doses than genital herpes 1.

Recurrent Episodes (Herpes Labialis)

For recurrent oral herpes, initiate treatment at the first sign of prodrome or within 24 hours of lesion onset with short-course, high-dose therapy:

Optimal regimens for recurrent herpes labialis:

• Valacyclovir 2 g twice daily for 1 day (single-day therapy)
• Famciclovir 1500 mg once or 750 mg twice daily for 1 day
• Acyclovir 400 mg 5 times daily for 5 days (alternative if above unavailable)

The evidence strongly supports that early initiation is critical—treatment must begin during prodrome or within 1-2 days of lesion onset to achieve meaningful benefit 1, 2, 3. Recent systematic reviews confirm that both topical and systemic therapies reduce lesion duration when applied early, but systemic therapy is superior 4.

Topical therapy considerations:

• Acyclovir 5% cream may reduce lesion duration if applied very early 3, 5
• Topical therapy is substantially less effective than oral antivirals and generally discouraged 6, 1
• Consider only when systemic therapy is contraindicated or unavailable

Suppressive Therapy for Frequent Recurrences

For patients with ≥6 recurrences per year, daily suppressive therapy reduces recurrence frequency by >75% 1, 6:

Suppressive regimens:

• Acyclovir 400 mg orally twice daily
• Valacyclovir 500 mg to 1 g orally once or twice daily
• Famciclovir 250 mg orally twice daily

Important caveats:

• After 1 year of continuous suppression, discontinue to reassess recurrence rate 1, 6
• Suppressive therapy does not eliminate asymptomatic viral shedding 1
• Safety documented for acyclovir up to 6 years, valacyclovir/famciclovir for 1 year 1

Severe or Complicated Disease

For severe oral HSV with complications (disseminated infection, encephalitis, or requiring hospitalization):

IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days or until clinical resolution 6

Special Populations

Immunocompromised patients:

• Require more aggressive therapy with longer treatment courses 6
• Higher risk of acyclovir-resistant strains requiring alternative agents (foscarnet) 6, 7
• Consider prophylactic oral acyclovir to reduce frequency and severity 5

HIV-infected patients:

• May have prolonged episodes requiring extended therapy 6
• Monitor closely for treatment failure

Key Clinical Pitfalls

1. Timing is everything: Most treatment failures occur because therapy is initiated too late. Patients should have medication on hand to start at first prodromal symptoms 2, 3.

2. Avoid topical monotherapy: Topical acyclovir has substantially inferior efficacy compared to oral therapy and should not be the primary treatment 6, 1.

3. Don't undertreate first episodes: Primary oral HSV can be severe and always warrants systemic antiviral therapy, not just symptomatic management 1.

4. Resistance concerns: While acyclovir resistance exists, it has not been associated with treatment failure in immunocompetent patients 6. Resistance is primarily a concern in immunocompromised populations 7.

Emerging Evidence

Recent research (2025) highlights that novel helicase-primase inhibitors show promise for overcoming resistance and may provide better viral suppression 7. However, current standard-of-care remains the nucleoside analogues (acyclovir, valacyclovir, famciclovir) based on decades of safety and efficacy data 4, 7.

The most recent systematic review (2025) confirms that systemic antivirals target both lesion resolution and recurrence prevention, making them superior to topical agents for comprehensive HSV management 4.